GSK-923295

Term ID

CHEBI:234356

Synonyms

3-chloro-N-[(2S)-1-[(N,N-dimethylglycyl)amino]-3-(4-{8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl}phenyl)propan-2-yl]-4-(propan-2-yloxy)benzamide
GSK 295
GSK 923295
GSK 923295A
GSK-295
GSK-923295A
GSK295
GSK923295
GSK923295A

Definition

An imidazopyridine that is imidazo[1,2-a]pyridine substituted by 4-{(2S)-2-[3-chloro-4-(propan-2-yloxy)benzamido]-3-[(N,N-dimethylglycyl)amino]propyl}phenyl, and (1S)-1-hydroxyethyl groups at positions 2 and 8, respectively. It is an allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity (K_i = 3.2 nM and 1.6 nM for human and canine CENP-E motordomains, respectively).

References

cas:1088965-37-0
drugbank:DB06097
lincs.smallmolecule:LSM-45692
patent:WO2010102157
pubmed:20167803
pubmed:21584937
pubmed:22020315
pubmed:22948716
pubmed:24900171
pubmed:25725449
pubmed:26320186
pubmed:27368372
pubmed:29982103
pubmed:30681497
pubmed:31530389
pubmed:32351712
pubmed:32442423
pubmed:32679092
pubmed:32698529
pubmed:33237480
pubmed:33804489
pubmed:35037651
pubmed:37728741
pubmed:38258067
pubmed:39327243
pubmed:39701545
pubmed:39737806
pubmed:39818172

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from GSK-923295

Phenotype where environments contain GSK-923295

Phenotype modified by environments containing GSK-923295

Phenotype affecting GSK-923295

Human Disease Model